MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1571)	5/26/2005 12:33:55 PM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma "outperform" Thursday, May 26, 2005 6:23:54 AM ET Robert W. Baird NEW YORK, May 26 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $35. In a research note published this morning, the analysts mention that the company has developed a robust clinical pipeline apart from its key drug, Aloxi. MGI Pharma's Dacogen drug, with its impressive 17% overall response rate, has a good chance of receiving an approval on or around September 1, the analysts say. The company is expected to file an NDA for its Saforis drug by the end of 3Q05, Robert W Baird adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next